[布加替尼治疗非小细胞肺癌的最新进展]
[Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib].
作者信息
Yu Jia, Ren Shengxiang
机构信息
Department of Oncology, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200082, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2025 Jun 20;28(6):450-459. doi: 10.3779/j.issn.1009-3419.2025.106.12.
Abstract
The discovery of anaplastic lymphoma kinase (ALK) tyrosine kinase gene rearrangement mutations in non-small cell lung cancer (NSCLC) has driven continuous advancements in ALK-targeted therapies. The next generation of ALK tyrosine kinase inhibitor, Brigatinib, has demonstrated significant efficacy in patients with ALK-positive NSCLC, offering clinical benefits in deep response of tumor, treatment of brain metastases patients, quality of life, and long-term survival. This review will provide current advancements and exploratory directions for Brigatinib. .
摘要
在非小细胞肺癌（NSCLC）中发现间变性淋巴瘤激酶（ALK）酪氨酸激酶基因重排突变推动了ALK靶向治疗的不断进步。新一代ALK酪氨酸激酶抑制剂布加替尼已在ALK阳性NSCLC患者中显示出显著疗效，在肿瘤深度缓解、脑转移患者治疗、生活质量和长期生存方面带来临床益处。本综述将介绍布加替尼的当前进展和探索方向。
相似文献
1
[Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib].[布加替尼治疗非小细胞肺癌的最新进展]
Zhongguo Fei Ai Za Zhi. 2025 Jun 20;28(6):450-459. doi: 10.3779/j.issn.1009-3419.2025.106.12.
2
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶（<I>ALK</I>）重排非小细胞肺癌的靶向治疗。
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
3
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.比较伴有 ALK 重排的晚期非小细胞肺癌一线治疗的疗效和安全性：临床试验的荟萃分析。
BMC Cancer. 2021 Nov 26;21(1):1278. doi: 10.1186/s12885-021-08977-0.
4
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.布加替尼和劳拉替尼：它们对非小细胞肺癌中 ALK 抑制剂的影响，重点关注耐药突变和中枢神经系统转移。
Jpn J Clin Oncol. 2021 Jan 1;51(1):37-44. doi: 10.1093/jjco/hyaa192.
5
High efficacy of brigatinib for brain metastases in ALK fusion gene-positive non-small cell lung cancer: A case series.ALK 融合基因阳性非小细胞肺癌脑转移的布加替尼高疗效：病例系列。
Thorac Cancer. 2024 Feb;15(6):496-499. doi: 10.1111/1759-7714.15207. Epub 2023 Dec 30.
6
Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.布加替尼用于治疗ALK阳性的晚期非小细胞肺癌患者。
Drugs Today (Barc). 2017 Aug;53(8):435-446. doi: 10.1358/dot.2017.53.8.2676119.
7
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.一线治疗晚期间变性淋巴瘤激酶突变型非小细胞肺癌患者的疗效和安全性：系统评价和网络荟萃分析。
Cancer. 2023 Apr 15;129(8):1261-1275. doi: 10.1002/cncr.34664. Epub 2023 Feb 7.
8
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.劳拉替尼、阿来替尼和布加替尼在初治/未治疗的ALK阳性晚期非小细胞肺癌中的比较：一项系统评价和网状Meta分析
J Chemother. 2022 Apr;34(2):87-96. doi: 10.1080/1120009X.2021.1937782. Epub 2021 Jun 17.
9
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).洛拉替尼与其他间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKI）作为一线治疗ALK 阳性晚期非小细胞肺癌（NSCLC）的比较：系统评价和网络荟萃分析。
Lung Cancer. 2024 Nov;197:107968. doi: 10.1016/j.lungcan.2024.107968. Epub 2024 Sep 29.
10
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.识别晚期 ALK 阳性非小细胞肺癌一线和二线治疗中最优的 ALK 抑制剂：系统评价和网络荟萃分析。
BMC Cancer. 2024 Feb 8;24(1):186. doi: 10.1186/s12885-024-11916-4.
本文引用的文献
1
Real-world evidence of brigatinib as second-line treatment after crizotinib for ALK+ non-small cell lung cancer using South Korean claims data (K-AREAL).使用韩国索赔数据（K-AREAL）评估克唑替尼后布加替尼作为 ALK+ 非小细胞肺癌二线治疗的真实世界证据。
Cancer Med. 2024 Jul;13(14):e70030. doi: 10.1002/cam4.70030.
2
Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study.brigatinib 治疗 ROS1 融合阳性非小细胞肺癌的 II 期研究：Barossa 研究。
ESMO Open. 2024 Aug;9(8):103642. doi: 10.1016/j.esmoop.2024.103642. Epub 2024 Jul 16.
3
Brigatinib in -Related Schwannomatosis with Progressive Tumors.布加替尼治疗相关进行性肿瘤性神经鞘瘤病。
N Engl J Med. 2024 Jun 27;390(24):2284-2294. doi: 10.1056/NEJMoa2400985. Epub 2024 Jun 21.
4
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.ALK 阳性 NSCLC 二代 ALK-TKIs 时代的进展模式、耐药机制及后续治疗。
J Transl Med. 2024 Jun 20;22(1):585. doi: 10.1186/s12967-024-05388-0.
5
Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China.6种酪氨酸激酶抑制剂作为中国ALK阳性非小细胞肺癌一线治疗的成本效益分析
Clin Med Insights Oncol. 2024 May 31;18:11795549241257234. doi: 10.1177/11795549241257234. eCollection 2024.
6
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
7
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome.同时抑制 ALK 和 SRC 激酶会破坏 ALK 肺肿瘤细胞的蛋白质组。
Drug Resist Updat. 2024 May;74:101081. doi: 10.1016/j.drup.2024.101081. Epub 2024 Mar 19.
8
Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.唾液酸转移酶 ST3GAL4 赋予奥希替尼耐药性，并为克服非小细胞肺癌的耐药性提供策略。
Cancer Lett. 2024 Apr 28;588:216762. doi: 10.1016/j.canlet.2024.216762. Epub 2024 Feb 24.
9
Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.病例报告：ALK 阳性肺鳞癌晚期的临床完全缓解：ALK-TKIs 治疗失败后抗 PD-1 免疫治疗成功的病例研究。
Front Immunol. 2024 Feb 6;15:1360671. doi: 10.3389/fimmu.2024.1360671. eCollection 2024.
10
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.识别晚期 ALK 阳性非小细胞肺癌一线和二线治疗中最优的 ALK 抑制剂：系统评价和网络荟萃分析。
BMC Cancer. 2024 Feb 8;24(1):186. doi: 10.1186/s12885-024-11916-4.
Zotero 插件